Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 3, 2007, Pages

  Font Llitjós, Mariona ^a,c   Feliubadaló, Lídia ^a   Espino, Meritxell ^a,c   Clèries, Ramon ^a   Mañas, Sandra ^a,c   Frey, Isabelle M ^d   Puertas, Sara ^a,c   Colell, Guillem ^a,c   Palomo, Sergio ^a   Aranda, Jessica ^a   Visa, Joana ^a   Palacín, Manuel ^b,c   Nunes, Virginia ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Calculi; Cystinuria model; D penicillamine treatment; Noninvasive imaging system

Indexed keywords

AMINO ACID DERIVATIVE; CYSTINE; PENICILLAMINE; THIOL DERIVATIVE; TIOPRONIN;

AMINO ACID ANALYSIS; AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; CONTROLLED STUDY; CYSTINURIA; DISEASE SEVERITY; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; MALE; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SLC3A1 GENE; SLC7A9 GENE; SOLUBILIZATION; URINARY EXCRETION; UROLITHIASIS; VALIDATION PROCESS;

EID: 34548607872     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00121.2007     Document Type: Article

References (42)

1. Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163: 1419-1423, 2000.
2. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 20: 1003-1005, 2006.
3. Birwe H, Hesse A. High-performance liquid chromatographic determination of urinary cysteine and cystine. Clin Chim Acta 199: 33-42, 1991.
4. Calonge MJ, Gasparini P, Chillarón J, Chillón M, Gallucci M, Rousaud F, Zelante L, Testar X, Dallapiccola B, Di Silverio F, Barceló P, Estivill X, Zorzano A, Nunes V, Palacín M. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 6: 420-425, 1994.
5. Calonge MJ, Volpini V, Bisceglia L, Rousaud F, de Sanctis L, Beccia E, Zelante L, Testar X, Zorzano A, Estivill X, Gasparini P, Nunes V, Palacín M. Genetic heterogeneity in cystinuria: the SLC3A1 gene is linked to type I but not to type III cystinuria. Proc Natl Acad Sci USA 92: 9667-9671, 1995.
6. Coward RJ, Peters CJ, Duffy PG, Corry D, Kellett MJ, Choong S, van't Hoff WG. Epidemiology of paediatric renal stone disease in the UK. Arch Dis Child 88: 962-965, 2003.
7. Crawhall JC. Experience with penicillamine in the treatment of cystinuria. J Rheumatol Suppl 7: 100-102, 1981.
8. Crawhall JC, Watts RW. Some complications observed in the treatment of cystinuria with D- penicillamine and N-acetyl- D-penicillamine. Postgrad Med J Suppl: 8-11, 1968.
9. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H, Kanai Y. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 274: 28845-28848, 1999.
10. Chow GK, Streem SB. Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 156: 1576-1578, 1996.
11. Dahlberg PJ, van den B, Kurtz SB, Wilson DM, Smith LH. Clinical features and management of cystinuria. Mayo Clin Proc 52: 533-542, 1977.
12. Das SK, Ray K. Wilson's disease: an update. Nat Clin Pract Neurol 2: 482-493, 2006.
13. Dello Strologo L, Pras E, Pontesilli C, Beccia E, Ricci-Barbini V, de Sanctis L, Ponzone A, Gallucci M, Bisceglia L, Zelante L, Jiménez-Vidal M, Font M, Zorzano A, Rousaud F, Nunes V, Gasparini P, Palacín M, Rizzoni G. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 13: 2547-2553, 2002.
14. Ece A, Ozdemir E, Gurkan F, Dokucu AI, Akdeniz O. Characteristics of pediatric urolithiasis in south-east Anatolia. Int J Urol 7: 330-334, 2000.
15. Erbagci A, Erbagci AB, Yilmaz M, Yagci F, Tarakcioglu M, Yurtseven C, Koyluoglu O, Sarica K. Pediatric urolithiasis - evaluation of risk factors in 95 children. Scand J Urol Nephrol 37: 129-133, 2003.
16. Faerber GJ. Pediatric urolithiasis. Curr Opin Urol 11: 385-389, 2001.
17. Feliubadaló L, Arbonés ML, Mañas S, Chillarón J, Visa J, Rodés M, Rousaud F, Zorzano A, Palacín M, Nunes V. Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis. Hum Mol Genet 12: 2097-2108, 2003.
18. o,+ AT) of rBAT. International Cystinuria Consortium. Nat Genet 23: 52-57, 1999.
19. 0,+ AT heterodimer is the main apical reabsorption system for cystine in the kidney. Am J Physiol Renal Physiol 283: F540-F548, 2002.
20. Fjellstedt E, Denneberg T, Jeppsson JO, Christensson A, Tiselius HG. Cystine analyses of separate day and night urine as a basis for the management of patients with homozygous cystinuria. Urol Res 29: 303-310, 2001.
21. Font-Llitjós M, Jiménez-Vidal M, Bisceglia L, Di Perna M, de Sanctis L, Rousaud F, Zelante L, Palacín M, Nunes V. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 42: 58-68, 2005.
22. Font M, Feliubadaló L, Estivill X, Nunes V, Golomb E, Kreiss Y, Pras E, Bisceglia L, d'Adamo AP, Zelante L, Gasparini P, Bassi MT, George AL Jr, Manzoni M, Riboni M, Ballabio A, Borsani G, Reig N, Fernández E, Zorzano A, Bertran J, Palacín M. Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-type I cystinuria. Hum Mol Genet 10: 305-316, 2001.
23. Friedman M. Applications of the ninhydrin reaction for analysis of amino acids, peptides, and proteins to agricultural and biomedical sciences. J Agric Food Chem 52: 385-406, 2004.
24. Friedrich VL, Zimmerman F. Zur Pharmakologie von D-Penicillamin. Arzneim Forsch (Drug Res) 25: 162-168, 1975.
25. Goodyer P. The molecular basis of cystinuria. Nephron Exp Nephrol 98: e45-e49, 2004.
26. Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med 17: 343-348, 2006.
27. Harbar JA, Cusworth DC, Lawes LC, Wrong OM. Comparison of 2-mercaptopropionylglycine and D-penicillamine in the treatment of cystinuria. J Urol 136: 146-149, 1986.
28. Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 20: 19-24, 2005.
29. Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, Walkley SU, Covey DF, Schaffer JE, Ory DS. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci USA 103: 13807-13812, 2006.
30. Leclerc D, Boutros M, Suh D, Wu Q, Palacín M, Ellis JR, Goodyer P, Rozen R. SLC7A9 mutations in all three cystinuria subtypes. Kidney Int 62: 1550-1559, 2002.
31. Montgomery DC. Design and Analysis of Experiments. New York: Wiley, 1997.
32. Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136: 1003-1008, 1986.
33. Palacín M, Goodyer P, Nunes V, Gasparini P. Cystinuria. New York: McGraw-Hill, 2002.
34. Palacín M, Nunes V, Font-Llitjós M, Jiménez-Vidal M, Fort J, Gasol E, Pineda M, Feliubadaló L, Chillarón J, Zorzano A. The genetics of heteromeric amino acid transporters. Physiology (Bethesda) 20: 112-124, 2005.
35. Pastore A, Massoud R, Motti C, Lo Russo A, Fucci G, Cortese C, Federici G. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urine. Clin Chem 44: 825-832, 1998.
36. Pfeiffer R, Loffing J, Rossier G, Bauch C, Meier C, Eggermann T, Loffing-Cueni D, Kuhn LC, Verrey F. Luminal heterodimeric amino acid transporter defective in cystinuria. Mol Biol Cell 10: 4135-4147, 1999.
37. Pierides AM. Clinical aspects of cystinuria. Contrib Nephrol 122: 167-172, 1997.
38. Pras E. Cystinuria at the turn of the millennium: clinical aspects and new molecular developments. Mol Urol 4: 409-414, 2000.
39. R Development-Core-Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2006.
40. o,+ is fully functional in the absence of the heavy subunit. EMBO J 21: 4906-4914, 2002.
41. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786, 2005.
42. Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 108: 705-710, 2006.